Extension Letter Agreement to Collaboration and License Agreement between AstraZeneca and Regulus Therapeutics Inc.
Contract Categories:
Intellectual Property
›
License Agreements
Summary
AstraZeneca and Regulus Therapeutics Inc. have agreed to extend the termination date of their existing Collaboration and License Agreement by twelve months, moving the effective termination date to June 8, 2019. This extension allows AstraZeneca to complete all activities related to AZD4076 and gives both parties time to finish the required transfer activities under the agreement. The extension is confirmed by signatures from both companies' representatives.
EX-10.1 2 ex-101xazletteragreement.htm EXHIBIT 10.1 Exhibit
Exhibit 10.1
AstraZeneca R&D Gothenburg ∙ SE-431 83 Mölndal ∙ Sweden
T: +46 31 776 10 00 ∙ F: +46 31 776 37 00 ∙ astrazenenca.com
Visitors: Pepparedsleden 1 ∙ Mölndal
Mr. Joseph Hagan
President and Chief Executive Officer
Regulus Therapeutics Inc.
10614 Science Center Dr.
San Diego, CA 92121
Confidential
May 8, 2018
Dear Mr. Hagan:
AstraZeneca requests to extend the Collaboration and License Agreement termination effective date by an additional twelve (12) months to allow AstraZeneca to complete all activities involving AZD4076. By the end of this 12-month extension, AstraZeneca and Regulus will complete the transfer activities contemplated by the agreement.
The new termination effective date pursuant to the extension will be June 8, 2019. Kindly confirm your acceptance of this extension by your signature below.
Sincerely,
/s/ Regina Frische-Danielson
__________________________
Regina Fritsch-Danielson, PhD
Vice President and Head of CVRM, Innovate Medicines and Early Development
ACCEPTED AND AGREED:
Regulus Therapeutics Inc.
/s/ Joseph Hagan
____________________________
By: Joseph Hagan
President and CEO
